Ardelyx   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: Fremont CA United States (2007)

Organization Overview

First Clinical Trial
2010
NCT02819687
First Marketed Drug
2019
tenapanor (Ibsrela)
First NDA Approval
2019
tenapanor (Ibsrela)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ardelyx | Ardelyx, Inc. | ARDELYX INC